Investors

Press Releases

ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

January 23, 2019

Geneva, Switzerland and Boston, MA – January 23, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019

January 2, 2019

Geneva, Switzerland and Boston – January 2, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of…

Read more
 
 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.